

Fred Hutch/UWMC Kidney Cancer Studies

Localized

Adjuvant

**Metastatic
First Line**

**Metastatic
Second Line +**

TELIX Zircon study PET/CT imaging of ccRCC with IRM
[NCT03849118](#)
PI: Chen / Coordinator: Tsang

Merck MK6482-022: Belzutifan (MK-6482) + Pembro (MK-3475) vs Placebo + Pembro, in the Adjuvant Treatment of (ccRCC) Post Nephrectomy
[NCT05239728](#)
PI: Tykodi | Coordinator: Jacobs

iPREDICT Trial: PET/CT study for Patients with Metastatic malignancies receiving Immunotherapy
RG1121794 PI: Chen | Coordinator: Tsang

Merck MK6482-011: Belzutifan + Lenvatinib vs Cabozantinib for pts who have progressed after prior PD-1/PDL-1 therapy
[NCT04586231](#), RG1121694
PI: Tykodi | Coordinator: Jacobs

NiKang NKT2152 101: Phase 1 study of HIF-2-alpha inhibitor in patients with advanced clear cell renal cell carcinoma
RG1122075
[NCT05119335](#) PI: Hall | Jacobs

KEY: Open: **Green/Bold**
Not Yet Open: *Blue/Italicized*
Non-therapeutic:

For more information, search the NCT# at clinicaltrials.gov or refer a patient by calling (206) 606-1062.